PedAM
Pediatric Disease Annotations & Medicines
| leishmaniasis | ||||
| Disease ID | 118 |
|---|---|
| Disease | leishmaniasis |
| Manually Symptom | UMLS | Name(Total Manually Symptoms:17) C2707258 | infections C2364133 | infection C1000483 | anemia C0700502 | primary hypothyroidism C0497156 | adenopathy C0333300 | phagedena C0263313 | pemphigus foliaceus C0206061 | interstitial pneumonitis C0038826 | superinfections C0037285 | skin manifestations C0032059 | placentitis C0026848 | muscular disease C0024291 | hemophagocytic syndrome C0022660 | acute renal failure C0019080 | hemorrhage C0018923 | haemangiosarcoma C0011633 | dermatomyositis |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:4) C0009450 | infection | 31 C0021311 | infections | 4 C0026848 | muscular disease | 1 C0024291 | hemophagocytic syndrome | 1 |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:4) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0023281 | atovaquone | D053626 | 94015-53-9 | leishmaniasis | MESH:D007896 | therapeutic | 21809846 | ||
| C0023281 | miltefosine | C039128 | - | leishmaniasis | MESH:D007896 | therapeutic | 17205440 | ||
| C0023281 | nelfinavir | D019888 | 159989-64-7 | leishmaniasis | MESH:D007896 | therapeutic | 20361030 | ||
| C0023281 | nitric oxide | D009569 | 10102-43-9 | leishmaniasis | MESH:D007896 | marker/mechanism | 17218153 | ||
FDA approved drug and dosage information(Total Drugs:1) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D007896 | inomax | nitric oxide | 100PPM Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons | GAS;INHALATION | Discontinued | None | Yes | No |
FDA labeling changes(Total Drugs:1) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D007896 | 12/21/2010 | inomax | nitric oxide | Prevention of bronchopulmonary dysplasia | INOmax is not indicated for prevention of BPD in preterm neonates d 34 weeks gestational age.Efficacy for the prevention of BPD in preterm infants was not established in three ldouble-blind, placebo-controlled clinical trials in a total of 2,149 preterm infants Information on clinical trials, adverse reaction | Labeling | B | - | - | - | INO Therapeutics | 2/11/2010 | FALSE' |